

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-13. (cancelled)

14. (currently amended) A DNA transfer vector comprising [[a]] at least one of the nucleotide sequences selected from the group consisting of SEQ ID NO: ~~1, 2, 3, 4, 5,~~
~~6, 8, 9, 10, 11,~~ 12, 13, and 14.

15. (previously presented) The DNA transfer vector according to claim 14, wherein said vector is a plasmid.

16. (currently amended) The DNA transfer vector ~~of~~ according to claim 15, further comprising a transcription promotor.

17. (currently amended) The DNA transfer vector ~~of~~ according to claim 16, wherein the transcription promotor is CMV.

18. (currently amended) The DNA transfer vector ~~of~~ according to claim 15, further comprising 4 CpG motifs.

19. (currently amended) The DNA transfer vector ~~of~~
according to claim 18, further comprising 8 CpG motifs.

20. (previously presented) A pharmaceutical composition
comprising a DNA transfer vector according to claim 14 in
admixture with pharmaceutically acceptable vehicles and
excipients.

21. (previously presented) The pharmaceutical
composition according to claim 20, wherein said composition is in
a form for parenteral administration.

22. (cancelled)

23. (withdrawn - currently amended) A combined
pharmaceutical preparation comprising at least two different DNA
transfer vectors according to claim 14, ~~for simultaneous,~~
~~sequential or separate therapeutic use.~~

24-26. (cancelled)

27. (new) The DNA transfer vector according to claim
14, comprising the nucleotide sequence of SEQ ID NO: 2.

28. (new) The DNA transfer vector according to claim 14, comprising the nucleotide sequence of SEQ ID NO: 12.

29. (new) The DNA transfer vector according to claim 14, comprising the nucleotide sequence of SEQ ID NO: 13.

30. (new) The DNA transfer vector according to claim 14, comprising the nucleotide sequence of SEQ ID NO: 14.